Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL - Dr Kanti Rai
Just in case you haven't heard the news, 'There have been “very exciting” developments over the last decade in the treatment of CLL, Dr Kanti Rai (of CLL Rai staging fame) told HemOnc Today': healio.com/hematology-oncol...
Very encouraging to hear from such an expert. 🍻
find it of interest... pharmastrategyblog.com/2013...
here. [ cllsociety.org/2016/05/ash-... ] I also...
instead of the CLL Society website, but I thought the contrast of the broad approval of ibrutinib frontline...
Start a Community